Trial Profile

A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Relmacabtagene-autoleucel (Primary) ; Cyclophosphamide; Fludarabine
Indications Diffuse large B cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

06 Nov 2019 Results of trials NCT03344367 and NCT03355859 released at the 61st Annual Meeting and Exposition of the American Society of Hematology
06 Nov 2019 Results of a pooled data analysis from NCT03344367 and NCT03355859 trials released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
23 Aug 2019 Results published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com